New two-year data for Roche’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss February 11, 2022February 22, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New two-year data for Roche’s Vabysmo and Susvimo…New two-year data confirm Roche’s Vabysmo improves…The Lancet publishes studies showing Roche’s…The Lancet publishes studies showing Roche’s…FDA approves Roche’s Vabysmo, the first bispecific…FDA approves Roche’s Vabysmo, the first bispecific…
